These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 7804373)

  • 21. Antitumor effects of a new interleukin-2 slow delivery system on methylcholanthrene-induced fibrosarcoma in mice.
    Fujiwara T; Sakagami K; Orita K
    J Cancer Res Clin Oncol; 1990; 116(2):141-8. PubMed ID: 2324156
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enhancement of therapeutic effect of interleukin-2 on spontaneous pulmonary metastases of Lewis lung carcinoma by killer helper factor associated with increased induction of killer activity.
    Fukuta K; Sone S; Kitahara M; Okada M; Ogura T
    Jpn J Cancer Res; 1989 Jun; 80(6):562-7. PubMed ID: 2503476
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Augmentation of interleukin-2 immunotherapeutic effects by lymphokine-activated killer cells and allogeneic stimulation in murine tumor cells.
    Eggermont AM; Steller EP; Ottow RT; Matthews W; Sugarbaker PH
    J Natl Cancer Inst; 1987 Nov; 79(5):983-90. PubMed ID: 3500357
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Successful combination immunotherapy for the generation in vivo of antitumor activity with anti-CD3, interleukin 2, and tumor necrosis factor alpha.
    Yang SC; Fry KD; Grimm EA; Roth JA
    Arch Surg; 1990 Feb; 125(2):220-5. PubMed ID: 2137327
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cure of human melanoma lung metastases in nude mice with chronic indomethacin therapy combined with multiple rounds of IL-2: characteristics of killer cells generated in situ.
    Lala PK; Elkashab M; Kerbel RS; Parhar RS
    Int Immunol; 1990; 2(12):1149-58. PubMed ID: 2090199
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination treatment with irritant and recombinant interleukin 2 in the peritoneal cavity for evoking effective anti-tumor activity: generation of lymphokine-activated killer cells and tumor-specific killer cells.
    Uchida H; Taniguchi K; Nomoto K
    Jpn J Cancer Res; 1990 Apr; 81(4):416-24. PubMed ID: 2114394
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunotherapy of intraperitoneal cancer with interleukin 2 and lymphokine-activated killer cells reduces tumor load and prolongs survival in murine models.
    Ottow RT; Steller EP; Sugarbaker PH; Wesley RA; Rosenberg SA
    Cell Immunol; 1987 Feb; 104(2):366-76. PubMed ID: 3493081
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhanced antimetastatic activity of lymphokine-activated killer cells purified and expanded by their adherence to plastic.
    Schwarz RE; Vujanovic NL; Hiserodt JC
    Cancer Res; 1989 Mar; 49(6):1441-6. PubMed ID: 2784350
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vivo boosting of lung natural killer and lymphokine-activated killer cell activity by interleukin-2: comparison of systemic, intrapleural and inhalation routes.
    Flexman JP; Manning LS; Robinson BW
    Clin Exp Immunol; 1990 Oct; 82(1):151-6. PubMed ID: 2208789
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interleukin-18 in combination with IL-2 enhances natural killer cell activity without inducing large amounts of IFN-gamma in vivo.
    Arai N; Akamatsu S; Arai S; Toshimori Y; Hanaya T; Tanimoto T; Ikeda M; Tomura M; Fujiwara H; Kurimoto M
    J Interferon Cytokine Res; 2000 Feb; 20(2):217-24. PubMed ID: 10714558
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Augmentation of murine lymphokine (rIL-2)-activated killer cell activity by indomethacin.
    Chao TY; Ohnishi H; Chu TM
    Mol Biother; 1989; 1(6):318-22. PubMed ID: 2610950
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Induction by interleukin-7 of lymphokine-activated killer activity in lymphocytes from autologous and syngeneic marrow transplant recipients before and after systemic interleukin-2 therapy.
    Pavletic Z; Benyunes MC; Thompson JA; Lindgren CG; Massumoto C; Alderson MR; Buckner CD; Fefer A
    Exp Hematol; 1993 Sep; 21(10):1371-8. PubMed ID: 8359237
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
    Mulé JJ; Yang J; Shu S; Rosenberg SA
    J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Augmentation of human lymphokine-activated killer cell activity in splenic lymphocytes by the combination of low-dose interleukin 2 plus interleukin 3.
    Okuno K; Ohnishi H; Shilayama Y; Hirohata T; Ozaki M; Yasutomi M
    Mol Biother; 1992 Jun; 4(2):83-6. PubMed ID: 1515099
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human lymphokine-activated killer cells augment immunotherapy of human colon carcinoma xenografts with monoclonal antibody D612.
    Pendurthi TK; Schlom J; Primus FJ
    J Immunother (1991); 1991 Feb; 10(1):2-12. PubMed ID: 2012797
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunotherapy of mammary adenocarcinoma metastases in C3H/HeN mice with chronic administration of cyclo-oxygenase inhibitors alone or in combination with IL-2.
    Khoo NK; Chan FP; Saarloos MN; Lala PK
    Clin Exp Metastasis; 1992 Jul; 10(4):239-52. PubMed ID: 1617832
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
    Mulé JJ; Ettinghausen SE; Spiess PJ; Shu S; Rosenberg SA
    Cancer Res; 1986 Feb; 46(2):676-83. PubMed ID: 3484431
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Application of an interleukin 2 slow delivery system to the immunotherapy of established murine colon 26 adenocarcinoma liver metastases.
    Fujiwara T; Sakagami K; Matsuoka J; Shiozaki S; Uchida S; Fujioka K; Takada Y; Onoda T; Orita K
    Cancer Res; 1990 Nov; 50(21):7003-7. PubMed ID: 2208166
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phenotype and cytolytic activity of mouse tumor-bearer splenocytes and tumor-infiltrating lymphocytes from K-1735 melanoma metastases following anti-CD3, interleukin-2, and tumor necrosis factor-alpha combination immunotherapy.
    Yang SC; Fry KD; Grimm EA; Roth JA
    J Immunother (1991); 1991 Oct; 10(5):326-35. PubMed ID: 1790140
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhanced cell-mediated cytotoxicity by interferon-gamma and interleukin-2 against syngeneic murine mammary adenocarcinoma.
    Nakajima I; Chu TM
    Mol Biother; 1992 Mar; 4(1):47-52. PubMed ID: 1627274
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.